Condition
Helicobacter-associated Gastritis
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 3 (1)
P 4 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02422706Phase 3UnknownPrimary
Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori
NCT01888237Phase 4Completed
High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication
NCT01434992CompletedPrimary
Detection of Helicobacter Pylori Infection by High Resolution Endoscopy
Showing all 3 trials